BWI: Sun Pharma Settles Litigation over Generic Stalevo ® and Comtan ®

Press release from Business Wire India
Source: Sun Pharmaceuticals Industries Ltd
Tuesday, June 22, 2010 11:16 AM IST (05:46 AM GMT)
Editors: General: Consumer interest; Business: Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
--------------------------------------------------
Sun Pharma Settles Litigation over Generic Stalevo ® and Comtan ®


Mumbai, Maharashtra, India, Tuesday, June 22, 2010 -- (Business Wire India) -- Sun Pharmaceutical Industries Ltd announced that together with its affiliates ("Sun Pharma") it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the United States against Sun Pharma regarding submission of Abbreviated New Drug Applications (ANDAs) for generic versions of Stalevo® and Comtan® tablets.

Under the terms of the settlement agreement, Sun Pharma will be able to launch generic versions of 25/100/200 mg and 37.5/150/200 mg strengths of Stalevo ® tablets in the US on 1 April 2012. In addition to these strengths, Sun Pharma will be able to launch generic versions of other strengths of Stalevo ® product on 2 October 2012 and generic versions of Comtan ® product on 1 April 2013, unless certain conditions relating to launch are fulfilled even earlier. The parties have agreed that Orion will supply these generic product versions to Sun Pharma. Other terms of the settlement are confidential.

These agreements will be subject to review by the US Federal Trade Commission and the US Department of Justice.

Stalevo ® and Comtan ® are registered trademarks of Orion Corporation.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The Company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.


CONTACT DETAILS
Uday Baldota, Sun Pharmaceuticals Industries Ltd, +91 22 6645 5645, Xtn 605/ +91 (22) 66455605/ +91 9867010529, uday.baldota@sunpharma.com
Mira Desai, Sun Pharmaceuticals Industries Ltd, +91 (22) 6645 5645, Xtn 606/ +91 (22) 66455606/ +91 9821923797, mira.desai@sunpharma.com

KEYWORDS
CONSUMER, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE, 524715.BO, SUNPHARMA .NS

If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.

Submit your press release at http://www.businesswireindia.com